INTRODUCTION

The dual-antiplatelet therapy (taking orally aspirin together with ticagrelor or clopidogrel) is used to inhibit platelet activating and aggregating and has been the cornerstone treatment in acute coronary syndrome (ACS) patients after percutaneous coronary intervention (PCI). Although ticagrelor showed fast, consistent, and effective results among ACS patients, the bleeding incidence was higher than...
clopidogrel. Compared with treatment by aspirin and clopidogrel, a latest KAMIR-NIH research showed that aspirin together with ticagrelor or prasugrel displayed a similar risk of all-cause mortality but an elevating bleeding risk. Hence, clopidogrel might be a better treatment in East Asian ACS patients.

Clopidogrel, by inhibiting P2Y12 receptor, could prevent adenosine diphosphate-induced platelets aggregation and lower the incidence of major adverse cardiovascular events (MACE) in ACS sufferers after PCI. While different patients responded greatly to clopidogrel treatment. Approximately 10%-40% of patients continue to manifest adverse cardiovascular risk. This effect may be due to the failure of platelet inhibition responding to clopidogrel, a clinical phenomenon named clopidogrel resistance (CR). Moreover, by VerifyNow P2Y12 assay, some researchers have noted that P2Y12 reaction units (PRU) higher than 240 could indicate the existence of CR. But, the CR pathogenesis remains not clearly understood. Many extrinsic factors could influence platelet activity after taking clopidogrel, such as comorbidities, drug interactions, and smoking. Among these factors, diabetes mellitus (DM) may be an important clinical factor attributed to platelet dysfunction. The mechanisms involved in hyperreactive platelets in DM patients have been suggested to be insulin deficiency, hyperglycemia, metabolic conditions, and cellular abnormalities.

The glucokinase gene (GCK), sited on 7p15.3-p15.1, codes the glucose enzyme. Through catalyzing the rate-limiting step of insulin secretion, GCK participates in balancing glucose homeostasis and glycogen synthesis. Many studies have indicated that GCK plays a vital role in diabetes. Through systemic analysis of gene expression profiles, one study revealed that the GCK gene played a role in obese type 2 diabetes. Another study investigated the effect of DNA methylation on obesity and type 2 diabetes mellitus and found that DNA hypermethylation could lead to a decline in hepatic GCK expression and was correlated with susceptibility to diabetes. Additionally, if GCK DNA methylation changes, then glucose homeostasis in F1 offspring would be disrupted after maternal bisphenol A exposure. Although our former studies showed that the DNA methylation of P2Y12 and PON1 might be associated with CR, the effect of GCK DNA methylation on CR is not clearly understood. In this study, in ACS patients with clopidogrel treatment, we attempted to explore whether the selected CpG islands methylation in GCK is associated with CR.

2 | METHOD

2.1 | Samples

Seventy-two ACS patients were picked up in Ningbo No. 1 Hospital from September 2012 to December 2018. These patients, who complained of chest pain, were diagnosed by physical examination, laboratory tests, and coronary angiography. The followings were our inclusion criteria: (a) Based on recent ESC guideline, these ACS patients underwent PCI through drug-eluting stent; (b) before PCI, the patients received 300 mg clopidogrel and 300 mg aspirin as loading doses, and they were subsequently administered 75 mg clopidogrel and 100 mg aspirin daily as a maintenance doses; and (c) the patients were without aspirin low response (aspirin reaction units <550). And our exclusion criteria were shown as below: (a) chronic heart failure; (b) acute infection; (c) rheumatological disorders; (d) history of malignancy; (e) history of active bleeding; (f) abnormal hepatic or kidney function; (g) concomitant treatment using warfarin or IIb/IIa inhibitors (Tirofiban); and (h) platelets <150 000 μL or more than 500 000 μL.

Ethical approval was obtained for human sample collection from the Ethics Committees at Ningbo No. 1 Hospital, and all selected patients offered their written informed consent. The study protocol conformed to the principles outlined in the Declaration of Helsinki.

2.2 | Biochemical analyses and platelet function measurements

Blood samples from 36 CR and 36 NCR patients were collected, and their biochemical values, such as LDL, GLU, HbA1c, and BUN, were tested based on a standard process according to the manufacturer, and the raw data were collected.

The 2016 ACC/AHA guideline pointed out that the ACS patients, who would more likely to suffer the risk of CVD after PCI, were suggested to access platelet function. Thus, in this study, the patient platelet function was measured after 1 month since PCI. Through VerifyNow P2Y12 assay (Accumetrics Inc), platelet function was assessed to evaluate the responsiveness to P2Y12 antagonists. This turbidimetric-based optical detection system evaluated platelet aggregation as an increase in light transmittance from whole blood. The result was informed as PRU. And the PRU greater than 240 indicated the existence of clopidogrel resistance.

2.3 | DNA extraction and methylation assay

Human genomic DNA was extracted from leukocytes via the DNA Blood Mini Kit (Qiagen). DNA concentrations were determined by NANO DROP 1000 (Nanodrop) to ensure more than 500 ng/μL. GCK DNA methylation of cg01700200 and cg18492943 were assessed by bisulfite pyrosequencing. First, sodium bisulfite DNA conversion was carried out by EpiTech Bisulfite Kits. Then, polymerase chain reaction (PCR) amplification was operated using the PyroMark PCR Kit. Finally, the targeted CpG islands methylation was sequenced through PyroMark Qiagen Q96 reagents. Based on PyroMark Assay Design software, PCR primers and pyrosequencing primers were automatically planned, as shown in Table 1.

2.4 | Level of GCK mRNA determination

Using a RNeasy Plus Universal Kit (QIAGEN), RNA was separated from blood samples. One microgram of RNA along with the PrimeScript™ RT Reagent Kit and gDNA Eraser (Takara Bio) was used to generate cDNA. Then, after diluting the template cDNA, the relative expression of GCK mRNA was measured by the ABI 7500
SU et al. (Applied Biosystems). GAPDH was applied to normalize GCK expression. The relative quantitative was implemented via the comparative CT method ($\Delta \Delta C_t$). The amplification primers involving in qRT-PCR were schemed by Prime 5 software, and the sequences are shown in Table 2.

### 2.5 Statistical analysis

Statistical breakdown was operated with the software of PASW 18.0 (SPSS, Inc). A collection of association analyses were performed between mRNA expression, GCK DNA methylation, clinical indexes, and CR. Continuous variables that were not normally distributed are be described as medians with interquartile ranges (IQRs) and compared with non-parametric test, and normally distributed values are shown as the mean with standard deviation and compared by $t$ test. Additionally, categorical variables are expressed as the mean ± standard deviation and were evaluated by either chi-square tests or Fisher’s exact tests. The GCK mRNA expression levels are shown as the median with IQRs and compared with the $t$ test. Multiple linear regression was used to determine the effect between GCK DNA methylation and clinical features. Logistic regression was utilized for analyzing correlations between GCK methylation and biochemical elements among ACS patients suffered from clopidogrel resistance. A two-sided $P$ value, which was $< .05$, was regarded as statistically significant.

### 3 RESULTS

#### 3.1 Patient characteristics

From May 2010 to December 2018, a total of 72 CAD patients who met the above requirements were recruited in this study. Among these patients, 36 were considered CR. The clinical baselines of CR and NCR patients are presented in Table 3. Except for uric acid (UA), the other clinical indexes were well matched. This result indicated that higher uric acid might increase the CR risk.

#### 3.2 The association of CR and GCK DNA methylation

In the present research, according to the reference of our 850 k methylation chip, we chose cg01700200 (chr7:44227705-44227975) and cg18492943 (chr7:44203220-44203435) on GCK for bisulfite pyrosequencing. All of the genes were located on the gene body. We evaluated the association of the GCK DNA methylation between CR and NCR patients. As displayed in Figure 1 and Table 4, in targeted fragments, the methylation levels in cg01700200 and cg18492943 were not significantly interrelated with clopidogrel poor response.

Then, by different clinical baseline characteristics, we carried out a subunit analysis to estimate whether the GCK DNA methylation (cg01700200 and cg18492943) were associated with CR. We observed that in male patients without DM but suffering from dyslipidemia, higher methylation of cg18492943 indicated a risk of poorer clopidogrel response (male, NCR vs CR (%): 84.86 ± 6.29 vs 88.16 ± 4.32, $P = .032$; without DM, NCR vs CR (%): 84.66 ± 6.18 vs 88.16 ± 4.17, $P = .029$; and Dyslipidemia, NCR vs CR (%): 83.81 ± 6.96 vs 88.39 ± 4.74, $P = .042$). However, our study did not discover any significant relations between cg01700200 DNA methylation and poor response to clopidogrel, and there were no meaningful findings in other subgroups (Figure 2 and Table 5).

#### 3.3 The association of GCK mRNA expression and clopidogrel resistance

Through qRT-PCR, we assessed the relative mRNA expression in GCK to determine that the various GCK expression levels would influence on clopidogrel response. Unfortunately, the result was insignificant. While in a subgroup of patients without DM, we observed that GCK mRNA expression was decreased when patients were suffering from clopidogrel poor response (Figure 3).

#### 3.4 Regression analysis

For various clinical factors that might influence DNA methylation, we investigated the effect of these variables on GCK gene methylation through multiple linear regression, and we discovered that uric acid might be related to the methylation of cg18492943 ($F = 1.092, P$...
value = 0.041, $R^2 = 0.300$). Nevertheless, other confounding factors did not affect the methylation of cg01700200 and cg18492943. Moreover, in consideration of genetic and nongenetic factors influenced on clopidogrel response, we implemented a logistic regression analysis to assess the association between CR and these confounding factors. The results revealed that these variables (such as cg18492943, age, AST, TC, and PDW) were correlated with CR, while hypertension was protective factors of CR (Table 6).

Furthermore, since we performed logistic regression analysis in patients without DM, male, and dyslipidemia subgroups, the results indicated that in patients without DM, cg18492943, TG, TC, BUN, and PDW showed the risk of poor clopidogrel response, while cg01700200 was a protective factor (Table 7). However, the logistic regression analysis in other subgroups did not show any significant outcomes.

4 | DISCUSSION

Antiplatelet medicines (aspirin or clopidogrel) are commonly prescribed to reduce cardiovascular risk, especially in ACS patients after PCI. Patients taking antiplatelet drugs still experience bleeding or ischemic events, which represents a significant public health issue. Although new P2Y12 inhibitors, such as ticagrelor, could more rapidly, consistently, and effectively inhibit platelet activity, these drugs cause more bleeding events. A lately COSTIC research presented on 2018 ESC noted that clopidogrel was more suitable for Chinese. Hence, more investigations concerning the different responses to clopidogrel treatment, and personalized approaches to antiplatelet therapy in Chinese ACS patients are increasingly being considered. Since we carried out personalized approaches in antiplatelet treatment in clinical practice, we should note the existence of CR. A large number of studies have investigated the underlying mechanisms, and novel molecular mechanisms are continuously being discovered. For example, genetic polymorphisms (ABCB1, CYP2C19, and PON1) sometimes accounted for the risk of CR. However, polymorphisms failed to explain the gene-environment interaction, and accumulating evidence suggests that DNA methylation modification, which occurs at cytosine-phosphate-guanine (CpG) dinucleotide sites, is a reliable and stable epigenetic modification and can actively reshape pathological processes. Usually,
the hypermethylation of CpG islands (CGIs) might induce transcriptional silencing and influence the expression of targeted proteins. A recent investigation reported that aberrant DNA methylation might participate in the occurrence and development of atherosclerotic plaques and coronary heart disease. Furthermore, some studies have demonstrated that changes in ABCB1, ABCC3, P2Y12, and PON1 promoter methylation levels were associated with a decline in clopidogrel antiplatelet effects.

In the present study, according to the latest reference of our 850 k methylation chip (SUPPORTING INFORMATION), we found that in male patients without DM but suffering from dyslipidemia, higher cg18492943 methylation of the GCK gene indicated the occurrence of CR. In patients without DM, the expression of GCK mRNA was lower. Previous studies have also focused on the effect of GCK gene methylation on different diseases and physical disorders. Some studies discovered that hypomethylation in the GCK gene body was correlated to a risk of coronary heart disease and essential hypertension. However, few studies have paid close attention to the relationship between CR and GCK DNA methylation. Our recent results indicated that higher DNA methylation at cg18492943 could lead to lower the expression of GCK mRNA, which might contribute to CR in patients without DM. This effect might be due to glucostasis and metabolism. As this protein is predominantly produced in the pancreas, GCK catalyzes insulin secretion and participates in glycogen synthesis. The lower expression of the GCK gene would induce abnormal insulin secretion, leading to glucose instability. One study reported that elevated methylation in GCK CpG4 suggested higher risk for type 2 diabetes in Chinese males. DM patients exhibited an impaired response to clopidogrel, attributable to the attenuation of the PK profile of clopidogrel and an altered functional status of the P2Y12 signaling pathway. Hence, diabetes mellitus or pathoglycaemia was one of the major independent predictive factors for clopidogrel non-responsiveness. In our present cohort, for non-DM patients, the hypermethylation of cg18492943 on GCK might interfere with glucose stability, leading to the occurrence of CR. However, sample size limited our further evaluation and functional experiments on GCK methylation, such as cellular validation, are needed to further elucidate the inherent mechanism.

Except for the GCK gene, other aspects might also influence glucose regulation and the response to clopidogrel. Among these aspects, deficient insulin action is one of the most cardinal factors contributing to platelet dysfunction. Platelets express insulin receptors and insulin-like growth factor-1 (IGF-1) receptors. IGF-1 is present in granules of platelets, and its functional receptors are expressed on the platelet surface, leading to the amplification of platelet responses. Moreover, IGF-1 stimulation contributes to the phosphorylation of the IGF receptor and the tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) and IRS-2. The latter subsequently bound to the p85 subunit of phosphoinositide-3 kinase (PI3K), resulting in phosphorylation of the protein kinase B, which participated in several cellular responses to insulin as well as IGF-1 and was involved in the modulation of the platelet response. In addition, an increase in intracellular calcium promotes platelet degranulation and aggregation. IRS-1 may mediate the inhibition of Ca²⁺ mobilization through insulin. In T2DM patients, SNPs of rs956115 and rs13431554 in IRS-1 have hyperreactive platelets and

---

**TABLE 4** The comparison of GCK gene DNA methylation levels between CR and NCR patients

| Meth. (%) | NCR       | CR       | t   | P value |
|----------|-----------|----------|-----|---------|
| cg01700200 | 92.51 ± 2.60 | 91.53 ± 3.17 | 1.439 | .154     |
| cg18492943 | 85.33 ± 5.65 | 87.76 ± 4.65 | −1.995 | .050     |

---

**FIGURE 1** The comparison of cg01700200 and cg18492943 DNA methylation in GCK between CR and NCR patients

**FIGURE 2** The comparison of cg01700200 and cg18492943 DNA methylation in GCK between CR and NCR patients in the subgroups. (A, male patients, NCR vs CR (%): 84.86 ± 6.29 vs 88.16 ± 4.32, P = .032; B, patients without DM, NCR vs CR (%): 84.66 ± 6.18 vs 88.16 ± 4.17, P = .029; and C, patients with dyslipidemia, NCR vs CR (%): 83.81 ± 6.96 vs 88.39 ± 4.74, P = .042)
suffer from a risk of ischemic events. IRS-independent pathways contribute to platelet hyperreactivity due to impaired responses to nitric oxide (NO) and prostacyclin, which are related to CR. In our study, GCK, influenced by DNA methylation, could affect platelet activity in response to clopidogrel, which was also involved in insulin deficiency. However, the exact mechanisms of insulin action and CR have not been well established, and future discoveries will help us to understand the possible molecular factors and signaling pathways.

In addition to genetic factors, various extrinsic elements (drug interactions, comorbidities, and environment) may also result in CR. Our subgroup analysis and logistic regression analysis in present study discovered that hypertension decreased the CR risk, and cg18492943, PDW, TC, and UA may be positively associated with clopidogrel resistance. First, platelet distribution width (PDW) could manifest morphological changes in platelets, and platelet size was suggested as an indicator of enhanced reactivity; thus, the higher PDW might potentially increase the risk of complications after stenting. Another study demonstrated that the ratio of platelet to red cell distribution width (P-RDW) was lower in high on-treatment platelet reactivity (HPR) patients. As a result, an assessment of the role of PDW in planning antiplatelet therapy is warranted.

Second, we discovered that total cholesterol was a protective factor. This finding was similar to a recent study, which also reported that a poorer clopidogrel response was significantly associated with

| Index                  | Meth. (%) | NCR          | CR           | t     | P value |
|------------------------|-----------|--------------|--------------|-------|---------|
| DM                     |           |              |              |       |         |
| Yes (7 vs 11)          | cg01700200| 91.15 ± 2.63 | 91.71 ± 2.73 | −0.581|.569    |
|                        | cg18492943| 87.20 ± 1.72 | 86.85 ± 5.72 | 0.155 |.879    |
| No (29 vs 25)          | cg01700200| 92.84 ± 2.53 | 91.36 ± 3.39 | 1.834 |.072    |
|                        | cg18492943| 84.66 ± 6.18 | 88.16 ± 4.17 | −2.252|.029    |
| Male                   |           |              |              |       |         |
| Yes (26 vs 26)         | cg01700200| 92.63 ± 2.53 | 91.70 ± 3.37 | 1.136 |.261    |
|                        | cg18492943| 84.86 ± 6.29 | 88.16 ± 4.32 | −2.028|.032    |
| No (10 vs 10)          | cg01700200| 92.17 ± 2.88 | 91.07 ± 2.68 | 0.883 |.389    |
|                        | cg18492943| 86.55 ± 3.45 | 86.72 ± 5.54 | −0.083|.935    |
| Hypertension           |           |              |              |       |         |
| Yes (24 vs 25)         | cg01700200| 92.74 ± 2.78 | 91.22 ± 3.23 | 1.766 |.084    |
|                        | cg18492943| 85.09 ± 6.51 | 87.44 ± 5.19 | −1.404|.167    |
| No (12 vs 11)          | cg01700200| 92.05 ± 2.25 | 92.22 ± 3.07 | 0.218 |.877    |
|                        | cg18492943| 85.81 ± 3.55 | 88.49 ± 3.19 | 0.792 |.072    |
| Dyslipidemia           |           |              |              |       |         |
| Yes (16 vs 15)         | cg01700200| 92.27 ± 2.38 | 90.95 ± 3.99 | 0.047 |.270    |
|                        | cg18492943| 83.81 ± 6.96 | 88.39 ± 4.74 | −0.296|.042    |
| No (20 vs 21)          | cg01700200| 92.71 ± 2.81 | 91.94 ± 2.45 | 0.384 |.357    |
|                        | cg18492943| 86.54 ± 4.13 | 87.31 ± 4.65 | 0.330 |.578    |
| Hyperuricemia          |           |              |              |       |         |
| Yes (7 vs 14)          | cg01700200| 93.69 ± 3.56 | 91.64 ± 4.16 | 1.131 |.313    |
|                        | cg18492943| 85.03 ± 10.98| 85.41 ± 5.54 | −0.109|.090    |
| No (29 vs 22)          | cg01700200| 92.41 ± 2.60 | 91.21 ± 2.00 | 1.801 |.095    |
|                        | cg18492943| 86.92 ± 3.12 | 87.24 ± 5.06 | −0.178|.060    |
| Current smoking        |           |              |              |       |         |
| Yes (11 vs 13)         | cg01700200| 92.47 ± 2.45 | 91.84 ± 4.15 | 0.194 |.667    |
|                        | cg18492943| 85.85 ± 4.83 | 87.12 ± 4.56 | 0.963 |.341    |
| No (25 vs 23)          | cg01700200| 92.53 ± 2.71 | 91.35 ± 2.56 | 0.782 |.128    |
|                        | cg18492943| 85.10 ± 6.05 | 87.79 ± 4.80 | 0.870 |.097    |
| Alcohol abuse          |           |              |              |       |         |
| Yes (10 vs 6)          | cg01700200| 92.64 ± 2.29 | 92.13 ± 2.52 | 0.923 |.686    |
|                        | cg18492943| 84.71 ± 5.29 | 89.36 ± 5.34 | 0.834 |.112    |
| No (26 vs 30)          | cg01700200| 92.46 ± 2.75 | 91.41 ± 3.31 | 0.492 |.204    |
|                        | cg18492943| 85.57 ± 5.86 | 87.44 ± 4.53 | 0.826 |.183    |
levels of total cholesterol. Third, for the factors of uric acid and hypertension, the conclusions were not consistent. A previous correlation analysis revealed that hypertension and uric acid were risk factors for clopidogrel resistance, but another study showed that uric acid levels did not influence poor responses to clopidogrel. A systemic meta-analysis and larger sample trials would provide reliable conclusions.

To our knowledge, it was the first research exploring the association of GCK DNA methylation along with its mRNA relative expression with clopidogrel resistance. During this study, numerous attempts were made, but several inherent limitations were existed. First, we selected two fragments of the CGI from GCK, and there are likely other regions related to CR. Future analyses would help us to further our exploration. Second, based on animal cells or levels, functional experiments on GCK methylation are needed to validate the inherent mechanism in CR. Third, as gene-environment and gene-gene reciprocal interactions exist, unidentified confounding factors might change the expression GCK of genes and induce biased results. However, it is worthwhile to explore the molecular mechanism of clopidogrel resistance. Multicentre studies with large samples would optimize our discovery and further assessment.

To sum up, our study suggested that the higher methylation of cg18492943 in GCK gene could lead to a decline in GCK mRNA expression and potentially cause CR in patients without DM. Additionally, subgroup analysis and logistic regression analysis showed that the values of PDW, TC, and UA were interrelated with the incidence of CR, and hypertension lowered the CR risk. However, other advanced and effective planning studies with larger samples would facilitate the validity of our findings and the elucidation of CR pathogenesis.

**ACKNOWLEDGMENT**

We thank Dr Jin Yang for excellent technical assistance and editing the article.

**ORCID**

Jia Su [https://orcid.org/0000-0001-8940-4420](https://orcid.org/0000-0001-8940-4420)

**REFERENCES**

1. Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. *Eur J Pharmacol*. 2014;742:47-54.
2. Wiviott SD, Steg PG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. *Lancet*. 2015;386(9990):292-302.

**FIGURE 3** The comparison of GCK mRNA expression between CR and NCR patients in the subgroups. (A, male patients; B, patients without DM; and C, patients with dyslipidemia)

**TABLE 6** Logistic regression analysis in CR and NCR patients

|        | B    | Std. Error | Wald | P value | Exp (B) (95% C.I) |
|--------|------|------------|------|---------|-------------------|
| cg18492943 | 0.128 | 0.066      | 3.773 | .052    | 1.137 (0.999,1.293) |
| Age    | 0.059 | 0.034      | 3.016 | .082    | 1.060 (0.992,1.133) |
| TC     | 1.117 | 0.371      | 9.058 | .003    | 3.272 (0.158,0.677) |
| T      | 0.007 | 0.003      | 7.585 | .006    | 1.008 (1.002,1.013) |
| PDW    | 1.108 | 0.429      | 6.663 | .010    | 3.030 (1.306,7.029) |
| Hypertension | −1.425 | 0.712 | 4.010 | .045    | 0.241 (0.060,0.970) |
| Constant | −27.943 | 9.666 | 8.357 | .004    | 0.000 |

**TABLE 7** Logistic regression analysis in the subgroup without DM

|        | B    | Std. Error | Wald | P value | Exp (B) (95% C.I) |
|--------|------|------------|------|---------|-------------------|
| cg01700200 | −0.338 | 0.150 | 5.108 | .024 | 0.713 (0.532,0.956) |
| cg18492943 | 0.275 | 0.129 | 4.522 | .033 | 1.317 (1.022,1.698) |
| TC     | 0.687 | 0.351 | 3.843 | .050 | 0.503 (0.253,1.000) |
| TG     | 2.096 | 0.831 | 6.361 | .012 | 8.130 (1.595,41.434) |
| BUN    | 0.401 | 0.262 | 2.341 | .126 | 1.493 (0.894,2.494) |
| PDW    | 1.084 | 0.617 | 3.084 | .079 | 2.956 (0.882,9.908) |
| Constant | −12.610 | 19.449 | 0.420 | .517 | 0.000 |
3. Kang J, Han JK, Ahn Y, et al. Third-generation P2Y12 inhibitors in East Asian Acute Myocardial Infarction Patients: a nationwide prospective multicentre study. Thromb Haemost. 2018;118(3):591-600.

4. Jneid H, Addison D, Bhatt DL, et al. 2017 AHA/ACC clinical performance and quality measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2017;70(16):2048-2090.

5. Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37(4):390-399.

6. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45(8):1157-1164.

7. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2004;48(9):1742-1750.

8. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119(2):237-242.

9. Cayla G, Hulot JS, O’Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;306(16):1765-1774.

10. Faggioni M, Baber U, Chandrasekhar J, et al. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. Int J Cardiol. 2019;275:31-35.

11. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndromes. Circulation. 2011;123(7):798-813.

12. Iynedjian PB. Mammalian glucokinase and its gene. Biochem J. 1993;293(Pt 1):1-13.

13. Sternisha SM, Miller BG. Molecular and cellular regulation of human glucokinase. Arch Biochem Biophys. 2019;663:199-213.

14. Shen J, Zhu B. Integrated analysis of the gene expression profile and methylation with the risk of clopidogrel resistance in patients with type 2 diabetes. Mol Med Rep. 2018;17(6):7636-7644.

15. Jiang M, Zhang Y, Liu M, et al. Hypermethylation of hepatic glucokinase and L-type pyruvate kinase promoters in high-fat diet-induced obese rats. Endocrinology. 2011;152(4):1284-1289.

16. Li G, Chang H, Xia W, Mao Z, Li Y, Xu S. F0 maternal BPA exposure induced glucose intolerance of F2 generation through DNA methylation change in Gck. Toxicol Lett. 2014;228(3):192-199.

17. Su J, Li X, Yu Q, et al. Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. Biomed Res Int. 2014;2014:450814.

18. Su J, Li J, Yu Q, et al. Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease. J Clin Lab Anal. 2019;33(5):e22867.

19. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of st-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 acc/aha guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e122-155.

20. Kim IS, Jeong YH, Kang MK, et al. Correlation of high post-treatment platelet reactivity assessed by light transmission aggregometry and the VerifyNow P2Y12 assay. J Thromb Thrombolysis. 2010;30(4):486-495.

21. Terrier J, Daali Y, Fontana P, Csajka C, Reny JL. Towards personalized antithrombotic treatments: focus on P2Y12 inhibitors and direct oral anticoagulants. Clin Pharmacokinet. 2019;58(12):1517-1532.

22. Su J, Xu Li X, et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS ONE. 2012;7(10):e46366.

23. Tabata N, Hokimoto S, Akasaka T, et al. Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation. Thromb Res. 2014;134(5):939-944.

24. Pare G, Ross S, Mehta SR, et al. Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the clopidogrel in the unstable angina to prevent recurrent events trial and the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Circ Cardiovasc Genet. 2012;5(2):250-256.

25. Razin A, Webb C, Szfy M, et al. Variations in DNA methylation during mouse cell differentiation in vivo and in vitro. Proc Natl Acad Sci USA. 1984;81(8):2275-2279.

26. Avvik E, Babu M, Yla-Herttuala S. DNA methylation processes in atherosclerotic plaque. Atherosclerosis. 2019;281:168-179.

27. Ghaznavi H, Mahmoodi K, Soltanpour MS. A preliminary study of the association between the ABCA1 gene promoter DNA methylation and coronary artery disease risk. Mol Biol Res Commun. 2018;7(2):59-65.

28. Yang J, Zhou JS, Zhao YX, et al. ABCB1 hypomethylation is associated with decreased antiplatelet effects of clopidogrel in Chinese ischemic stroke patients. Pharmazie. 2015;70(2):97-102.

29. Yang J, Zhou JS, Zhang YD, Tian YY, Zou JJ. The association of ABC23 promoter methylation with clopidogrel response in Chinese ischemic stroke patients. Pharmazie. 2014;69(10):764-768.

30. Xu L, Zheng D, Wang L, et al. GCK gene-body hypomethylation is associated with the risk of coronary heart disease. Biomed Res Int. 2014;2014:151723.

31. Fan R, Wang WJ, Zhong QL, et al. Aberrant methylation of the GCK gene is associated with the risk of essential hypertension. Mol Med Rep. 2015;12(2):2390-2394.

32. Tang L, Ye H, Hong Q, et al. Elevated CpG island methylation of GCK gene predicts the risk of type 2 diabetes in Chinese males. Gene. 2014;547(2):329-333.

33. Angiolillo DJ, Jakubowski JA, Ferreiro JL, et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol. 2014;64(10):1005-1014.

34. Yaseen IF, Farhan HA, Abbas HM. Clopidogrel non-responsiveness in patients undergoing percutaneous coronary intervention using the VerifyNow test: frequency and predictors. Eur J Hosp Pharm. 2019;26(2):113-116.

35. Randriamboavonjy V, Fleming I. Insulin, insulin resistance, and platelet signaling in diabetes. Diabetes Care. 2009;32(12):2123-2130.

36. Hunter RW, Hers I. Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function. J Thromb Haemost. 2009;7(12):2123-2130.

37. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the IRS/PI3Kalpha pathway. Sci USA. 1984;81(8):2275-2279.
39. Angiolillo DJ, Bernardo E, Zanoni M, et al. Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2011;58(1):30-39.

40. Rivas Rios JR, Franchi F, Rollini F, Angiolillo DJ. Diabetes and antiplatelet therapy: from bench to bedside. Cardiovasc Diagn Ther. 2018;8(5):594-609.

41. Kern A, Gil RJ, Bojko K, et al. Platelet distribution width as the prognostic marker in coronary bifurcation treatment. Eur J Clin Invest. 2017;47(7):524-530.

42. Tomanik M, Koltowski L, Jonik S, et al. Platelet to red cell distribution width ratio for predicting clopidogrel efficacy in patients undergoing percutaneous coronary interventions: insights from the ONSIDE-TEST study. Pol Arch Intern Med. 2019;129(2):117-122.

43. Golukhova EZ, Grigoryan MV, Ryabinina MN, Bulaeva NI. High On-treatment platelet reactivity determinants on dual antiplatelet therapy in patients with ischemic heart disease before elective percutaneous coronary intervention. Kardiologiia. 2018;58(4):5-14.

44. Akturk IF, Caglar FN, Erturk M, et al. Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease. Clin Appl Thromb Hemost. 2014;20(7):749-754.

45. Barbieri L, Verdoia M, Pergolini P, et al. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. Nutr Metab Cardiovasc Dis. 2016;26(4):352-358.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Su J, Zheng N, Li Z, et al. Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients. J Clin Lab Anal. 2020;34:e23040. https://doi.org/10.1002/jcla.23040